No Data
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
CHARMACY PHAR To Go Ex-Dividend On May 22nd, 2024 With 0.32977 HKD Dividend Per Share
Charmacy Pharmaceutical to Pay Final Dividend
Chuangmei Pharmaceutical (02289.HK): Zheng Xiyue was elected as the employee representative supervisor of the Supervisory Board
Gelonghui, May 20, 丨 Chuangmei Pharmaceutical (02289.HK) announced that Zheng Xiyue was elected as the employee representative supervisor of the fourth board of supervisors at the company's employee congress held on May 20, 2024. He and the shareholder representative supervisors and independent supervisors of the 4th board of supervisors elected by the company on May 20, 2024 (“Annual General Meeting of Shareholders”) will form the fourth board of supervisors of the company.
No Data
